Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.

Published Date: 09 Jun 2023

According to a recent study by Nicholas Phillips and colleagues, adult cancer survivors are more likely to experience modifiable late-onset memory impairment.

Read Full News

Latest News

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

(This Aug 27 story has been republished, with no changes to text.)

Alzheimer's Blood Test Gets FDA Clearance

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood ⁠test to help identify signs of Alzheimer's disease in people aged 55 and older with...

Less Seniors Taking Inappropriate Cognitive Meds

Older adults with cognitive disorders who use inappropriate medications linked to adverse cognitive effects are more likely to have poor mental health-related quality of life.

US Health Department Seeks Public Feedback on Vaccine Guidelines After Trump Order

The U.S. health department said on Friday it was seeking public feedback on federal vaccine recommendations, including how they ⁠are categorized and communicated, after...

Cognitive Therapy Boosts Brain Function in Schizophrenia

Structured cognitive remediation therapy helps boost brain activity, working memory, and quality of life and reduce severity of symptoms in patients with schizophrenia, a trial shows.

Did Breast Cancer Radiation Cause This Weird Lung Problem?

Especially peculiar since the patient had no risk factors

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

(This Aug 27 story has been republished, with no changes to text.)

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood ⁠test to help identify signs of Alzheimer's disease in people aged 55 and older with...

Older adults with cognitive disorders who use inappropriate medications linked to adverse cognitive effects are more likely to have poor mental health-related quality of life.

The U.S. health department said on Friday it was seeking public feedback on federal vaccine recommendations, including how they ⁠are categorized and communicated, after...

Structured cognitive remediation therapy helps boost brain activity, working memory, and quality of life and reduce severity of symptoms in patients with schizophrenia, a trial shows.

Especially peculiar since the patient had no risk factors

News All Time

Whole Foods Recall; RFK Jr.'s Voting Problem; Glass Particles in Biosimilar

Health news and commentary gathered by MedPage Today staff

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

News, features, and commentary about cancer-related issues

Genomic Newborn Screening Could Identify Childhood Cancer Predisposition

Testing could give doctors an early start on life-preserving cancer treatments

SBRT Misses the Mark in Prostate Cancer Trial

No improvement over intensity-modulated RT in urinary symptoms after 2 years, DFS after 3 years

What Caused This Young Man's Bladder Cancer

Occupational exposure, family history make tempting hypotheses

Dramatic Increase in Active Surveillance Use for Prostate Cancer

Soared past 90% in VA system for low-risk disease, to 61% for favorable intermediate-risk disease

Melanoma Patient on Immunotherapy Develops Severe Dermatitis

Clinicians faced with presumed dermatologic AEs urged to consider all differentials

Early Sugar Exposure and Cancer Risk; Melanoma Vaccine Win; 'Antifreeze' for CAR-T

News, features, and commentary about cancer-related issues

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

Freeman’s Lobotomy to Deep Brain Stimulation: What Changed?

The history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

Preschool-aged children exposed to screens for extended daily periods face elevated prevalence of sleep disturbances.

US Mental Health Treatment Rates Rise But Gaps Persist

Treatment rates for US adults with psychiatric disorders are modestly higher than in previous decades, but only a third receive minimally adequate care, new research shows.

Cognitive Bias Modification App Fosters Alcohol Avoidance

An Australian-designed smartphone app uses personalized cognitive bias modification to help users reduce or avoid alcohol consumption.

Schizophrenia: Nighttime Light Tied to Metabolic Dysfunction

Higher vs lower nighttime light exposure is associated with increased risk for obesity, hypertension, and dyslipidemia in patients with schizophrenia, a study suggests.

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

Consistently low PSA levels failed to signal metastasis

A Sinister Etiology for Shoulder Pain

Patient presented with what was assumed to be rotator cuff injury

Recommended News For You

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.

Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

How breast tissue density affects your risk of breast cancer

Rectal Cancer 'Crisis'; Smells Like Cancer; Flushing Away Clues to Colon Cancer

A small rise in cancer was observed following the 1986 Chernobyl accident.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

Recommended Articles For You

The Surprising Role of Magnesium in Digestion, Sleep and Mental Health  

Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis 

A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures 

Tumor Microenvironment Readiness as a Predictor of Cancer Progression 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

2.

New methods show how fast breast cancers grow and how surgery delays affect cancer staging

3.

Some low-grade prostate cancers carry higher risks than biopsy suggests

4.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

5.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

1.

Unraveling the Mysteries of Hematocrit: How It Impacts Your Health

2.

Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy

3.

Clinical Pharmacology of Erythroid Maturation Pathway Regulators

4.

Precision Medicine for Bone Marrow Microenvironment Remodeling

5.

Everything You Need to Know About HTLV: A Comprehensive Guide 

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

2.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot